Alprazolam
Xanax and Trankimazin are different trade names for the same drug.
The active substance of Xanax is alprazolam. It belongs to a group of drugs called benzodiazepines (drugs with anxiolytic action). Xanax is indicated for the treatment of symptoms of anxiety disorders in adults, only in situations where the symptoms are severe, prevent normal functioning, or are very troublesome for the patient. This drug is intended for short-term use only.
Before starting treatment with Xanax, the patient should discuss it with their doctor.
Episodes of hypomania and mania have been reported in association with the use of Xanax in patients with depression. Before planned surgery, the doctor should be informed about the use of Xanax.
The patient should tell their doctor about all the drugs they are currently taking or have recently taken, as well as any drugs they plan to take.
If the patient is pregnant or breastfeeding, suspects she may be pregnant, or plans to have a child, she should consult her doctor before using this drug. The use of the drug during pregnancy is not recommended. If the drug is used during pregnancy or if the patient becomes pregnant while taking alprazolam, she should be examined for potential fetal risk. If it is necessary to administer the drug in the last period of pregnancy, high doses should be avoided and the newborn should be monitored. Benzodiazepines pass into breast milk in small amounts. Xanax should not be used during breastfeeding.
Xanax causes impairment of psychophysical fitness. Before taking Xanax, the patient should familiarize themselves with the current local traffic laws. While taking Xanax, the patient should not drive vehicles or operate machinery.
If the patient has previously been diagnosed with intolerance to some sugars, they should consult their doctor before taking the drug.
The drug contains less than 1 mmol (23 mg) of sodium per tablet, which means the drug is considered "sodium-free".
Each tablet of this drug contains 0.23 mg of sodium benzoate (15%).
This drug should always be taken according to the doctor's instructions. In case of doubts, the patient should consult their doctor or pharmacist. Xanax is available in the following doses: 0.25 mg, 0.5 mg, 1 mg, 2 mg. Treatment should be as short as possible. The doctor should frequently assess the patient's condition and the need to extend treatment, especially if the severity of the symptoms decreases and may not require pharmacological treatment. The total treatment time should not exceed 2-4 weeks. Long-term treatment is not recommended. At the start of treatment, the doctor will inform the patient about the limited duration of therapy, the gradual reduction of the dose during withdrawal, and the possibility of withdrawal reactions. During the use of benzodiazepines, including Xanax, dependence and emotional or physical dependence may develop. This risk may increase with the dose and duration of treatment, so the smallest effective dose should be used for the shortest possible time, and the need for continued treatment should be frequently assessed with the doctor. Recommended dose The dose is determined by the doctor based on the severity of symptoms and the patient's individual response to treatment. If severe side effects occur after administration of the initial dose, the doctor may decide to reduce the dose. Symptomatic treatment of anxiety disorders The recommended initial dose is 0.25 mg or 0.5 mg three times a day. The doctor may decide to increase it, depending on the patient's needs, to a maximum daily dose of 4 mg divided into smaller doses taken throughout the day.
Xanax should not be used in children and adolescents under 18 years of age.
The use of Xanax in patients with severe liver failure is contraindicated.
The recommended initial dose is 0.25 mg two or three times a day. If necessary, the doctor may decide to gradually increase the dose depending on the patient's tolerance to the drug. If side effects occur, the doctor will decide to reduce the initial dose.
Taking a higher than recommended dose of Xanax may cause: ataxia (motor incoordination), drowsiness, speech disorders, coma, and respiratory depression. If worrying symptoms occur, the patient should immediately consult their doctor.
A double dose should not be taken to make up for a missed dose.
The patient should not stop taking the drug on their own. Since the treatment is symptomatic, after its discontinuation, the symptoms of the disease may return. The doctor will decide to gradually reduce the dose. If the patient has any further doubts about the use of this drug, they should consult their doctor. Information on the use of Xanax, 2 mg If necessary, these tablets can be divided into halves or quarters. To do this, the tablet should be placed on a hard surface with the indentation facing down. By pressing it with your thumb, you can break the tablet into two equal parts containing 1 mg of alprazolam.
If necessary, each resulting part (half) can be further divided. To do this, they should be placed on a hard surface again with the indentation facing down and pressed with your thumb again. In this way, two quarters containing 0.5 mg of alprazolam are obtained from each half.
In this way, the following parts of Xanax tablets are obtained:
The obtained halves and (or) quarters of the tablets can be stored in a bottle.
Like all drugs, Xanax may cause side effects, although they do not occur in everyone. If any of the following side effects persist or are troublesome, the patient should inform their doctor. The occurrence of some side effects depends entirely on the patient's individual susceptibility and the dose of the drug. Side effects are usually observed at the beginning of therapy and disappear as treatment continues or when the dose is reduced. Frequency of side effects observed in clinical trials and after the drug was introduced to the market:
Additionally, especially in patients taking other psychotropic drugs, with mental disorders, or abusing alcohol, a paradoxical reaction may occur with symptoms such as anxiety. Other side effects have been observed rarely or very rarely: motor disorders, epilepsy, psychotic symptoms, a feeling of changed self, agranulocytosis (a significant decrease in the number of granulocytes), allergic reactions, or anaphylaxis (severe allergic reactions). Benzodiazepines may cause physical and psychological dependence. If physical dependence occurs, sudden discontinuation of Xanax may cause withdrawal symptoms: headache, muscle pain, increased anxiety, feeling of tension, agitation, disorientation, irritability, feeling of changed environment or self, impaired hearing, stiffness, and paresthesia of limbs, hypersensitivity to light, noise, and touch, hallucinations, and seizures. These symptoms are usually more severe in patients treated for a long time, with high doses of benzodiazepines, and in the case of sudden or rapid discontinuation of the drug.
If any side effects occur, including any side effects not listed in this leaflet, the patient should inform their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. By reporting side effects, more information can be collected on the safety of the drug.
The drug should be stored in a place invisible and inaccessible to children. Store at a temperature below 25°C. Store in normal humidity conditions. Do not use this drug after the expiration date stated on the packaging. The expiration date indicates the last day of the specified month. Medicines should not be thrown into the sewage system or household waste containers. The patient should ask their pharmacist how to dispose of unused medicines. This will help protect the environment.
White, elongated tablets divisible with the inscription "U 94" on one side and a triple dividing line on both sides of the tablet. The packaging contains 30 tablets in an HDPE bottle with a child-resistant cap made of PP with an inner MDPE coating, in a cardboard box. For more detailed information, the patient should contact the marketing authorization holder or the parallel importer.
Pfizer GEP, S.L. Avda. de Europa 20 B, Parque Empresarial La Moraleja, 28108 Alcobendas - Madrid, Spain
Pfizer Italia S.r.l., 63100, Località Marino del Tronto, Ascoli Piceno (AP), Italy
Delfarma Sp. z o.o., ul. Św. Teresy od Dzieciątka Jezus 111, 91-222 Łódź
Delfarma Sp. z o.o., ul. Św. Teresy od Dzieciątka Jezus 111, 91-222 Łódź Number of the marketing authorization in Spain, the country of export: 705067.4
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.